Navigation Links
Court Rules on First Set of Patents in FENTORA Litigation
Date:3/11/2011

FRAZER, Pa., March 11, 2011 /PRNewswire/ -- On March 11, 2011, the United States District Court for the District of Delaware issued a decision as to a portion of the patent litigation brought by Cephalon Inc. (Nasdaq: CEPH), ("Cephalon") and its wholly-owned subsidiary CIMA Labs, Inc., ("CIMA") against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., (collectively "Watson") pertaining to Cephalon's FENTORA® fentanyl buccal tablet product.  The Court ruled in Watson's favor on two of the three patents at issue in the case.  The Court has yet to rule on the third patent.

"This decision does not resolve the litigation," said Jerry Pappert, Cephalon's Executive Vice President and General Counsel.  "We remain confident in the strength of our claims with respect to the third patent.  In the interim, we are reviewing the court's opinion with respect to the first two patents and are evaluating our options, including an appeal."

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/

Cephalon Forward-Looking Statement

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.Contacts:MediaFritz BittenbenderO: 610 883-5855C: 610-457-7041fbittenb@cephalon.comNatalie de VaneC: 610 999-8756ndevane@cephalon.comInvestorsRobert (Chip) Merritt610-738-6376cmerritt@cephalon.com
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
(Date:5/24/2017)...  ivWatch LLC today announced the launch of ... enable seamless integration of ivWatch,s groundbreaking IV infiltration ... and other devices. By integrating ivWatch technology into ... health care customers deliver a higher level of ... therapy. "The ivWatch OEM Board provides ...
Breaking Medicine Technology:
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Fresenius Vascular ... in minimally invasive techniques to treat and manage a wide range of vascular conditions, ... rebranding initiative. With more than 65 centers represented by more than 40 local brands, ...
(Date:6/20/2017)... ... June 20, 2017 , ... MindTouch , the leading ... proud to announce Touchpoints integrations. MindTouch Touchpoints easily integrate product documentation ... to provide a seamless customer experience. , Truly “plug and play,” Touchpoints are ...
(Date:6/20/2017)... ... June 20, 2017 , ... New, state-of-the-art magnetic ... is providing physicians with advanced capabilities for diagnosing and treating disease. , ... enabling doctors to get a more accurate look inside the patient’s body. The ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... systems industry has been selected as the partner of choice by Amtrak to ... railroad service that provides medium- and long-distance intercity service in the contiguous United ...
(Date:6/20/2017)... Pass, OR (PRWEB) , ... June 20, 2017 ... ... Recently, on her nationally syndicated radio program, The Sharon Kleyne Hour Power of ... EyeMist®, Kleyne launched right in to the world’s water crisis and how it ...
Breaking Medicine News(10 mins):